Incontinentia pigmenti is a rare genetic condition characterised by skin, eye, teeth and central nervous system (CNS) abnormalities. The characteristic skin lesions of incontinentia pigmenti are present at birth or develop in the first few weeks of life in approximately 90% of patients.
Incontinentia pigmenti is also referred to as ‘Bloch-Sulzberger syndrome’, ‘Bloch-Siemens syndrome’, ‘melanoblastosis cutis linearis’, and ‘pigmenteddermatosis-Siemens-Bloch type’.
What causes incontinentia pigmenti?
Incontinentia pigmenti is a dominant X-linked disease. This means that the abnormal incontinentia pigmenti gene is located on one of the X chromosomes, which determine the sex of a child (XY=male; XX=female). Dominant X-linked disease means that a female with only one copy of the abnormal gene will show the disease, even though they have a normal gene on their other X-chromosome. Males who inherit the abnormal gene do not survive, resulting in miscarriage or stillbirth (X-linked dominant, male-lethal syndrome). Rarely incontinentia pigmenti is reported in males with Klinefelter syndrome (XXY syndrome) or as a result of spontaneous mutations.
The incontinentia pigmenti gene is localised on chromosome Xq28. This gene normally codes for the nuclear factor-KB essential modulator protein and is known as the IKBKG gene (formerly known as NEMO or NF-kappaB gene).
Genetics of Incontinentia pigmenti*
*Image courtesy Genetics 4 Medics
What does the IKBKG gene do?
The IKBKG gene is involved in the regulation of the cell’s division and programmed cell death.
How do mutations in IKBKG cause the symptoms of incontinentia pigmenti?
Mutations in the IKBKG gene prevent it from working, and cells that have the mutation are more prone to programmed cell death.
Cell death in the skin may present with blisters. These heal as the cells with the mutation die and are replaced by surrounding cells.
Cell death also affects the endothelial cells (cells lining blood vessel walls) in the brain. This causes abnormal vessels to develop, and leakage of proteins from the blood into the brain. This may cause seizures.
What are the cutaneous features of incontinentia pigmenti?
Progressive skin rashes are the main clinical feature of the disease. There are four recognised clinical stages but their sequence is irregular, their duration variable and they may overlap.
Stage 1: Vesicular
Most often affects extremities and scalp but can arise on any part of the body
Red, blister-like lesions
Often appear grouped in lines along the arms and legs (following so-called blaschko lines)
Present at birth or within the first 2 weeks of life in 90% of patients
May last from a few weeks to a few months and recur throughout the first few months of life
Vesicular stage of incontinentia pigmenti
Vesicular stage of incontinentia pigmenti
Stage 2: Verrucous
Wart-like or pustular lesions
Thick crusts or scabs form on top of healing blisters
Lesions may be darker in skin colour (hyperpigmentation)
May be present at birth but in 70-80% of patients evolves after the first stage
May last for months, but rarely longer than a year
Verrucous stage of incontinentia pigmenti
Stage 3: Hyperpigmented
Skin is darkened in a swirled pattern
Pigmentation ranges from blue-grey or slate to brown
Present at birth in 5-10% of patients but usually appears within the first few months of life in 90-98% of patients
Darkened patches may or may not be related to areas affected in stage 1 and 2
Heavy pigmentation tends to fade slowly with increasing age
Hyperpigmented stage of incontinentia pigmenti
Hyperpigmented stage of incontinentia pigmenti
Stage 4: Atrophic/ hypopigmented
Scar-like lesions develop during adolescence and persist into adulthood
Occur in 30-75% of patients
Appear as pale, hairless patches or streaks
Other organ involvement
Other organs may be affected in various ways in patients with incontinentia pigmenti. These manifestations may not be seen or recognised until infancy or early childhood.
Teeth
Abnormalities in more than 80% of patients
Delay in eruption of teeth (both baby and adult teeth affected)
Some teeth may be missing altogether
Teeth may be unusually shaped, typically pegged or cone-shaped
Nails
May be involved in up to 40% of patients
Nails may be ridged, pitted, thickened or completely disfigured
Usually, all or multiple fingernails and toenails are affected
Hair
Minor hair abnormalities in up to 50% of patients
Loss or lack of hair on the crown of the head
Absence of eyebrows and eyelashes
Hair may be coarse, wiry and lack lustre
Eyes
Eye defects occur in 20-35% of patients
Typically occur before age 5
The disease causes an abnormality in the growth of blood vessels in the inside of the eye resulting in scarring
Can cause blindness but may be treated if recognised early enough
Central nervous system
Neurological complications may occur in up to 30% of patients
The most common complication is seizures which usually develop within the first few weeks of life
Other manifestations include slow motor development, intellectual disability, spastic paralysis, cerebralatrophy
Other organ systems
Manifestations are rare
Skeletal abnormalities such as extra ribs, shortened limb, smaller head circumference and finger abnormalities
Heart abnormalities
Lung abnormalities
What is the treatment for incontinentia pigmenti?
There is no specific treatment for incontinentia pigmenti. The main goal is to prevent secondary bacterialinfection of skin lesions and to monitor closely the development of related problems. This should include regular dental care and close monitoring by an ophthalmologist for the first few years of life.
Book: Textbook of Dermatology. Ed Rook A, Wilkinson DS, Ebling FJB, Champion RH, Burton JL. Fourth edition. Blackwell Scientific Publications.
Conte MI, Pescatore A, Paciolla M, Esposito E, Miano MG, et al. Insight into IKBKG/NEMO locus: report of new mutations and complex genomic rearrangements leading to incontinentia pigmenti disease. Human Mutation [Hum Mutat] 2014 Feb; Vol. 35 (2), pp. 165–77. PubMed
Hand JL. What's new with common genetic skin disorders? Curr Opin Pediatr. 2015 Aug;27(4):460–5. PubMed
Jabbari A, Ralston J, Schaffer J. Incontinentia pigmenti. Dermatology Online Journal, 16(11). 2010. PubMed
Minić S, Trpinac D, Obradović M. Systematic review of central nervous system anomalies in incontinentia pigmenti. Orphanet Journal Of Rare Diseases. 2013(8):25. PubMed
Paller AS, Mancini AJ. Hurwitz Clinical Pediatric Dermatology 6th Ed.
Ridder DA, Wenzel J, Müller K, Töllner K, Tong XK et al. Brain endothelial TAK1 and NEMO safeguard the neurovascular unit. J Exp Med. 2015 Sep 21;212(10):1529–49. PubMed